<DOC>
	<DOCNO>NCT02184429</DOCNO>
	<brief_summary>This study design evaluate safety plasma concentration PF-06669571 healthy volunteer follow single multiple ascend dos PF-06669571 . Effect food PF-06669571 plasma concentration evaluate single dose PF-06669571 . During multiple dose phase , PF-06669571 administer daily 14 day</brief_summary>
	<brief_title>A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Female subject nonchildbearing potential must meet least one follow criterion : 1 . Achieved postmenopausal status , define follow : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum folliclestimulating hormone ( FSH ) level confirm postmenopausal state ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . All female subject ( include female tubal ligation females NOT documented hysterectomy , bilateral oophorectomy and/or ovarian failure ) consider childbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Treatment investigational drug within 30 day ( determined local requirement ) 5 halflives precede first dose study medication ( whichever longer ) . Screening supine blood pressure &gt; = 140 mm Hg ( systolic ) &gt; =90 mm Hg ( diastolic ) , follow least 5 minute rest . If BP &gt; =140 mm Hg ( systolic ) &gt; =90 mm Hg ( diastolic ) , repeat per local standard operating procedure ( SOP ) . If orthostatic change present deem clinically significant investigator , Subject exclude . For subject answer `` Yes '' Columbia Suicide Severity Rating Scale ( CSSRS ) question 4 5 , risk assessment do qualified mental health professional ( MHP : psychiatrist license PhD level clinical psychologist ) ass whether safe subject participate study . In addition , subject deem investigator significant risk suicidal violent behavior exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>First human</keyword>
	<keyword>single ascend dose study</keyword>
	<keyword>multiple ascend dose study</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>food effect</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>